Harrow Inc (HROW)

12:13 PM

Harrow Inc. Stock Analysis and ForecastExplosive wealth accumulation - PrintWeekIndia

12:13 PM

Jul 24, 2025

What drives Harrow Inc. stock priceFree Technical Analysis Support - PrintWeekIndia

Jul 24, 2025

Jul 23, 2025

What analysts say about Harrow Inc. stockFree Stock Market Trend Analysis - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Harrow Inc. a good long term investmentRapid capital growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - WV News

Jul 22, 2025

Jul 21, 2025

Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey

Jul 21, 2025

Jul 20, 2025

Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN

Jul 20, 2025

Jul 20, 2025

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View

Jul 20, 2025

Jul 19, 2025

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

Jul 19, 2025

Jul 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent

Jul 18, 2025

Jul 18, 2025

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare

Jul 18, 2025

Jul 18, 2025

Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook

Jul 18, 2025

Jul 17, 2025

Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest

Jul 17, 2025

Jul 17, 2025

Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency

Jul 17, 2025

Jul 17, 2025

Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView

Jul 17, 2025

Jul 17, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus

Jul 17, 2025

Jul 17, 2025

Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com Australia

Jul 17, 2025

Jul 17, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire

Jul 17, 2025

Jul 17, 2025

Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan

Jul 17, 2025

Jul 17, 2025

Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World

Jul 17, 2025

Jul 16, 2025

(HROW) Trading Report - news.stocktradersdaily.com

Jul 16, 2025

Jul 16, 2025

FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World

Jul 16, 2025

Jul 15, 2025

Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser

Jul 15, 2025

Jul 15, 2025

How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser

Jul 15, 2025

Jul 15, 2025

What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser

Jul 15, 2025